DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Characterizing and Predicting Drug Effects on Cognition

Information source: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cognitive Deficits

Intervention: Topiramate (Drug); Lorazepam (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of Minnesota - Clinical and Translational Science Institute

Official(s) and/or principal investigator(s):
Susan E. Marino, PhD, Principal Investigator, Affiliation: Assistant Professor

Overall contact:
Susan E Marino, PhD, Phone: 612-624-2964, Email: marin007@umn.edu

Summary

Cognitive impairment is a widely reported side effect of many commonly used drugs. Even a mild, untoward effect on an essential function such a linguistic behavior, a directly observable product of complex cognitive processes, is disruptive to daily life. Nevertheless, the mechanisms underlying a drug's impact on cognition are poorly understood. This lack of understanding impedes the ability to predict both the effects of drugs in development and the degree to which an individual is vulnerable to the cognitive impact of a particular agent. Topiramate (TPM, an antiepileptic drug) is, with increasing frequency, being prescribed for a range of conditions including migraine prophylaxis, obesity and pain. It is a prime example of a drug that causes speech and language problems severe enough in some patients to result in discontinuation of therapy. For reasons not well understood, TPM has a poorer cognitive profile than many of the older antiepileptic drugs. The investigators' rational for this study is that it will offer insight into the mechanisms underlying drug-induced cognitive deficits.

Clinical Details

Official title: Characterizing and Predicting Drug Effects on Cognition

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Primary outcome: Relationship between neurocognitive performance and study drug plasma concentration

Secondary outcome: Neurophysiological effect of study drug on working memory

Detailed description: The investigators' long-term goal is to enhance clinical strategies and inform drug development in order to maximize the benefits of individual drug therapy while minimizing adverse cognitive/language-related side effects. The investigators' objective in this application is to elucidate the relationship among drug exposure as measured by plasma drug levels, its neurophysiological effects, and consequent effects on the cognitive processes observable in everyday language use. Using topiramate (TPM) as a prototype, the investigators will apply the tools of clinical pharmacology, computational linguistics, neuroscience, and engineering to the design and execution of randomized, double blind, crossover studies using three (3) doses of TPM, one (1) dose of a comparator drug (lorazepam-LZP) and a placebo. In order to isolate the cognitive effects of TPM from those possibly arising from an underlying medical condition, subjects will be healthy adults. The investigators will capitalize on an innovative system for automated language and speech analysis (SALSA) developed in our laboratory, to quantify the effects of TPM administration on effective language use, a crucial component of normal day-to-day functioning.

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy men and women

- Ages 18-50

- Women are post-menopausal or using approved birth control methods

- To control for brain lateralization of language functions, subjects need to have a

dominant right hand. Exclusion Criteria:

- Presence of clinically significant cardiovascular, endocrine, hematopoietic, hepatic,

renal, neurologic, and/or psychiatric disease including suicidality

- Vision or hearing impairments

- Current or a history of drug or alcohol abuse

- living outside of the Twin Cities Metropolitan area.

- The use of concomitant medications known to affect Topiramate (TPM), Lorazepam (LZP),

or the use of any concomitant medications that may alter cognitive function

- Prior adverse reaction or prior hypersensitivity to TPM, LZP or related compounds

- A positive pregnancy test (administered to all women before enrollment, and prior to

each study session).

- Subjects who have received any investigational drug within the previous 30 days

Locations and Contacts

Susan E Marino, PhD, Phone: 612-624-2964, Email: marin007@umn.edu

University of Minnesota, Minneapolis, Minnesota 55414, United States; Recruiting
Susan E Marino, PhD, Phone: 612-624-2964, Email: marin007@umn.edu
Kathy Fox, BSN, MBA, Phone: 612-626-8853, Email: foxxx005@umn.edu
Ilo E Leppik, MD, Sub-Investigator
Angela K Birnbaum, PhD, Sub-Investigator
Serguei V Pakhomov, PhD, Sub-Investigator
Mingzhou Ding, PhD, Sub-Investigator
Lynn Eberly, PhD, Sub-Investigator
Susan E Marino, PhD, Principal Investigator
Additional Information

Starting date: July 2013
Last updated: March 20, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017